key: cord-0687809-62q854c6
authors: Arslan, Umit; Borulu, Ferhat; Sarac, İbrahim; Prof, Bilgehan Erkut
title: Chronic intracardiac thrombus, a long‐term complication of COVID‐19: Case reports
date: 2021-07-26
journal: J Card Surg
DOI: 10.1111/jocs.15836
sha: 2fc0fa5f487bfd555254ab86981d4190c5504eee
doc_id: 687809
cord_uid: 62q854c6

Inflammation and thrombogenic effects of coronavirus disease 2019 (COVID‐19) can lead to cardiovascular complications in patients even after recovery from COVID‐19. Intracardiac thrombus is life‐threatening and can cause sudden death. Our study describes two patients who recovered from COVID‐19 and presented with chronic intracardiac thrombus.

Patients with coronavirus disease 2019 have an increased risk of thromboembolism, which can lead to life-threatening cardiovascular complications, such as acute myocardial infarction and intracardiac thrombus. 1, 2 Even in patients recovering from COVID-19, these complications pose potential risks to the cardiovascular system in the long term. Due to the severity of the inflammation and the tendency to develop thromboembolism, sudden deaths may occur due to the presence of a large thrombus. 3 

The clinical, laboratory, and demographic characteristics of two patients previously infected with COVID-19 when admitted to the hospital are presented in Table 1 .

An 80-year-old patient was diagnosed with COVID-19 two months ago and her hematological, biochemical, and inflammatory parameters at that time were as described in Table 2 . A telecardiogram, thoracic CT scan, and radiological examination revealed diffuse bilateral consolidation and peripheral ground-glass opacification, thereby confirming COVID-19 infection. The COVID-19 positive patient, whose oxygen saturation values decreased, was hospitalized and taken to intensive care. The patient was given breathing exercises and pressurized oxygen therapy, but without intubation. In addition, enoxaparin 6000 IU, favipiravir 200 mg, hydroxychloroquine 200 mg, ascorbic acid 1000 mg, and methylprednisolone 80 mg ampoule treatments were initiated. After 1 week of treatment, the oxygen saturation values of the patient increased and he was discharged on the 10th day. During the discharge phase, D-Dimer, ferritin, and fibrinogen levels decreased, although not at normal values. A CT performed due to an old COVID-19 infection revealed fibrotic changes in the lungs and a mass in the right ventricular cavity of the heart (Figure 1 ). Echocardiography revealed an immobile mass, approximately 3 × 5 × 6 cm in diameter, in the right atrium that was obstructing the flow of the vena cava inferior. T-PA infusion was given to dissolve the thrombus, but the thrombus did not shrink. During surgery, a mass covering one-third of the cavity, extending into the vena cava inferior, was demonstrated at the right atriotomy ( Figure 2A ,B). The mass was excised from the right atrial wall. In the postoperative period, the patient could not be taken off Abbreviations: ALT, alanine aminotransferase; AST, aspartate transaminase; CPB, cardiopulmonary bypass; CRP, C-reactive protein; CT, computed tomography; ICU, intensive care unit; INR, international normalized ratio; LDH, lactate dehydrogenase; t-PA, tissue plasminogen activator; WBC, white blood cell. the ventilator. Oxygen saturation was low and hemodynamic parameters were insufficient. The patient developed cardiopulmonary arrest on the fifth postoperative day and died.

A 78-year-old female patient was hospitalized with the diagnosis of COVID-19 3 months ago and the blood values at that time were as presented in Table 3 . The thorax CT showed ground-glass opacity that indicated bilateral lung involvement. In addition to oxygen therapy, medical treatment was initiated for COVID-19 infection (enoxaparin, antiviral agent, hydroxychloroquine, levofloxacin, and methylprednisolone). The patient was closely monitored for any thrombotic and hypercoagulation; after 10 days of treatment, the patient's clinical parameters and blood values began improving and she was discharged. Three months later, the patient was admitted to the neurology clinic due to a transient ischemic attack. Echocardiography revealed a mobile mass in the left atrium (Figure 3) , which was believed to be a thrombus. Coronary angiography was normal and the patient was given thrombolytic therapy to resolve the thrombus.

However, the thrombus did not shrink and a thrombus excision by surgery was decided upon. The mobile mass in the left atrium was removed ( Figure 4 ). The patient, who did not develop complications in the postoperative period, was discharged with Enoxaparin sodium 0.4 ml twice a day and then oral anticoagulant treatment 1 week later.

The two patients we present in this article represent two different cases of intracardiac thrombus due to underlying COVID-19 infec- In numerous case series, high D-Dimer levels have been reported in 40%-45% of patients associated with disease severity and increased mortality. 6 In our patients, D-Dimer levels increased in the first disease period, but the thrombotic process occurred after months. However, it is unclear when this thrombotic formation began after the disease. Therefore, we believe that even if the D-Dimer values are close to normal and the COVID-19 test is negative, as in our second patient, anticoagulant therapy for a few months would be beneficial. 

A case report of a large intracardiac thrombus in a COVID-19 patient managed with percutaneous thrombectomy and right ventricular mechanical circulatory support

Thrombo-embolism risk of COVID-19 is high and associated with a

L E 3 Blood parameters of the second patient at the time of COVID-19 infection

After COVID-19 test (+)

Ferritin (ng/ml) 501 (23

higher risk of mortality: a systematic review and meta-analysis

Right atrial thrombus in a COVID-19 child treated through cardiac surgery. Front Cardiovasc Med

COVID-19 and the cardiovascular system

Bi-atrial thrombosis in a patient with SARS-CoV-2 infection: a case report

COVID-19 related arterial coagulopathy

Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study

Coagulopathy and antiphospholipid antibodies in patients with COVID-19

Chronic intracardiac thrombus, a long-term complication of COVID-19: Case reports

The authors declare that there are no conflict of interests.

http://orcid.org/0000-0003-0695-5089Ferhat Borulu http://orcid.org/0000-0001-9731-9998İbrahim Sarac http://orcid.org/0000-0002-1574-2053Bilgehan Erkut Prof http://orcid.org/0000-0002-8771-3112